Ductal Carcinoma In Situ Recruiting Phase 2 Trials for Ruxolitinib (DB08877)

Also known as: Ductal carcinoma in situ / [M]Intraductal carcinoma, non-infiltrating NOS / Carcinoma, Intraductal, Noninfiltrating / Carcinoma in situ of breast ductal / Intraductal carcinoma in situ of breast / Intraductal proliferative breast lesion

IndicationStatusPhase
DBCOND0037614 (Ductal Carcinoma In Situ)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02928978Ruxolitinib for Premalignant Breast DiseasePrevention